Jeremy Force

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

23h-index2.1kcitations130works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(48), Immunotherapy and Immune Responses(26), Breast Cancer Treatment Studies(23), CAR-T cell therapy research(23), Advanced Breast Cancer Therapies(17)

Publications130 total

Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
A Phase I Trial of Alpelisib Combined with Capecitabine in Patients with HER2-negative Metastatic Breast Cancer
UNC Libraries·2025Open Access
Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
Clinical Cancer Research·2025· 3 citedOpen Access
Inhibition of transcriptional cyclin-dependent kinases, CDK12/13, as a treatment for colorectal cancer with CDK12 upregulation.
Journal of Clinical Oncology·2025· 2 cited
Cryoablation of bone, soft tissue, and nerve in the setting of uninterrupted systemic cancer therapies
Clinical Imaging·2025· 1 cited
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
UNC Libraries·2024Open Access
A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer·2024Open Access
Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and aPD-1 enable sustained antitumor responses against established HER2 breast cancer
UNC Libraries·2024Open Access
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
ClinicoEconomics and Outcomes Research·2024· 14 citedOpen Access
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses
UNC Libraries·2024Open Access
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
Annals of Oncology·2023· 46 citedOpen Access
Discovery of oncogenic <i>ROS1</i> missense mutations with sensitivity to tyrosine kinase inhibitors
EMBO Molecular Medicine·2023· 12 citedOpen Access
The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective
Journal of Medical Economics·2023· 6 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Terry Hyslop(9), Jennifer K. Plichta(8), Oluwadamilola M. Fayanju(7), Rachel A. Greenup(7), Laura H. Rosenberger(7), Kelly Westbrook(7), Yi Ren(6), Samantha M. Thomas(6), E. Shelley Hwang(5), Adam Brufsky(5), Sarah Sammons(5), Judah Folkman(4), John V. Heymach(4), Carey K. Anders(4), Gloria Broadwater(4), P. Kelly Marcom(4), Zachary C. Hartman(3), E. Shelley Hwang(3), Giuseppe Giaccone(3), James V. Alvarez(3)